

# INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

## MEETING MINUTES

**Meeting Date:** Friday, May 22, 2026  
**Time:** 11:00 am Arizona Time  
**Location:** Zoom Teleconference  
**Institution:** Retinal Research Institute, LLC, Phoenix, AZ  
**Principal Investigator:** Neal Palejwala, MD  
**Protocol:** Adverum Biotechnologies, ADVM-022-14  
**NCT Number:** N/A  
**Meeting Type:** Initial Review of Protocol and Site  
**Title:** Evaluation of the safety and tolerability of Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy in the second (contralateral) eye of participants with bilateral neovascular age-related macular degeneration

### 1. Call to order:

The Meeting was called to order at 11:00 am Arizona Time.

### 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Three voting members were present, including one local member unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Review of proposed research:

The Chair provided an overview of the protocol.

The Chair provided an overview of the biosafety risk assessment for the protocol.

### 7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for ADVM-022, since it consists of an AAV vector administered by injection in a clinical setting.

The Committee determined that IBC oversight will continue for **3 months after the last subject's last dose of ADVM-022 locally**, provided that other biosafety criteria for study closure are also met.

### 8. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3

NO: 0

ABSTAIN: 0

### 9. Review of Principal Investigator qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

## INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **10. Review of proposed facilities and practices:**

The Chair provided an overview of the arrangement for the facilities and practices.

#### **Point of Discussion:**

1. The Committee had no questions or concerns about the facilities and practices.

### **11. Site requirements:**

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

### **12. Vote on the Site:**

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 3

NO: 0

ABSTAIN: 0

### **13. Advice to the Institution:** None.

**14. Meeting adjourned:** The meeting was adjourned at 11:10 am Arizona Time.

**15. Post-meeting notes:** None.

### **Documents reviewed:**

Agenda

Protocol, Version 0.0, dated 02-19-2026

Investigator's Brochure, Edition 9.0, dated 02-25-2026

Investigational Medicinal Product Manual, Version 1.0, dated 05-06-2026

Biological Risk Assessment and Summary, updated 05-12-2026

Site Map, dated 05-14-2026

Site Inspection Checklist, expires 08-26-2026, updated 05-13-2026

Photos, dated 05-14-2026

Biohazard Sign, ADVN-022, dated 05-18-2026

SOP, Biosafety for ADVN-022, dated 05-14-2026

Training, Shipping Certification, expires 08-12-2027

CV, Palejwala, N., signed 10-09-2024